Research programme: cytomegalovirus infections - GPC Biotech
Latest Information Update: 22 Jan 2007
At a glance
- Originator GPC Biotech AG
- Class Small molecules
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cytomegalovirus infections
Most Recent Events
- 10 Apr 2000 Preclinical development for Cytomegalovirus infections in Germany (Unknown route)